Cumulative life course impairment in psoriasis: Patient perception of disease-related impairment throughout the life course

British Journal of Dermatology

Volumn 164, Issue SUPPL. 1, 2011, Pages 1-14

  Warren, R B ^a   Kleyn, C E ^a   Gulliver, W P ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; CAREER; CASE REPORT; COMORBIDITY; COPING BEHAVIOR; DISEASE COURSE; DISEASE SEVERITY; FAMILY; FEMALE; HUMAN; MALE; PATIENT ATTITUDE; PATIENT DECISION MAKING; PRIORITY JOURNAL; PSORIASIS; SOCIAL INTERACTION; STIGMA;

ADAPTATION, PSYCHOLOGICAL; ADULT; COST OF ILLNESS; EMPLOYMENT; FEMALE; HUMANS; LIFE CHANGE EVENTS; MALE; MIDDLE AGED; PERCEPTION; PSORIASIS; QUALITY OF LIFE; STEREOTYPING;

EID: 79953788708     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10280.x     Document Type: Article

References (103)

1. Kimball AB, Gieler U, Linder D, et al., Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
2. Kuh D, Ben-Shlomo Y, eds. A Life Course Approach to Chronic Disease Epidemiology, 2nd edn. Oxford: Oxford University Press, 2004.
3. Elder GH Jr, Giele JZ, eds. The Craft of Life Course Research. New York: The Guilford Press, 2009.
4. Bhatti ZU, Finlay AY, Salek S,. Chronic skin diseases influence major life-changing decisions: a new frontier in health outcomes research. Br J Dermatol 2009; 161: 58-9.
5. Bhatti ZU, Salek S, Finlay AY,. The influence of chronic skin diseases on major life-changing decisions as a parameter for the assessment of long-term impact. Br J Dermatol 2010; 163: 39-40.
6. Bhatti Z, Salek M, Finlay A,. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol 2011; 25: 245-6.
7. Kimball A, Gieler U, Linder D, et al., Re: major life-changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol 2011; 25: 246.
8. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, et al., Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-5. (Pubitemid 36706221)
9. Ahlehoff O, Gislason GH, Charlot M, et al., Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2010; doi:. Oct 29 (Epub ahead of print).
10. Abuabara K, Azfar RS, Shin DB, et al., Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-92.
11. Mehta NN, Azfar RS, Shin DB, et al., Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
12. Prodanovich S, Kirsner RS, Kravetz JD, et al., Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-3.
13. Gelfand JM, Troxel AB, Lewis JD, et al., The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-9. (Pubitemid 350277763)
14. Gulliver WP, Macdonald D, Gladney N, et al., Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. J Cutan Med Surg 2011; 15: 37-47.
15. Jobling R,. Psoriasis. BMJ 2007; 334: 953-4.
16. International Federation of Psoriasis Associations (IFPA). Under the spotlight: revealing the real life impact of psoriasis over time. 2010. Available at: (last accessed 2 March 2011).
17. Ginsburg IH, Link BG,. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol 1993; 32: 587-91. (Pubitemid 23274587)
18. Vardy D, Besser A, Amir M, et al., Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736-42. (Pubitemid 35286160)
19. Richards HL, Fortune DG, Griffiths CE, et al., The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15. (Pubitemid 32279929)
20. Richards HL, Fortune DG, Main CJ, et al., Stigmatization and psoriasis. Br J Dermatol 2003; 149: 209-11.
21. CPGC. Canadian guidelines for the management of plaque psoriasis. 2009. Available at: (last accessed 2 March 2011).
22. Weiss SC, Kimball AB, Liewehr DJ, et al., Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-18.
23. Fortune DG, Main CJ, O'Sullivan TM, et al., Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 1997; 42: 467-75. (Pubitemid 27254621)
24. Fortune DG, Richards HL, Corrin A, et al., Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. J Behav Med 2003; 26: 211-24. (Pubitemid 36682100)
25. Fox FE, Rumsey N, Morris M,. 'Ur skin is the thing that everyone sees and you cant change it!': exploring the appearance-related concerns of young people with psoriasis. Dev Neurorehabil 2007; 10: 133-41. (Pubitemid 47555457)
26. Kuh D, Ben-Shlomo Y, Lynch J, et al., Life course epidemiology. J Epidemiol Community Health 2003; 57: 778-83.
27. Kimball AB, Gladman D, Gelfand JM, et al., National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
28. Najarian DJ, Gottlieb AB,. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003; 48: 805-21. quiz 22-4. (Pubitemid 36706210)
29. Reich K, Kruger K, Mossner R, et al.,. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-7.
30. Boehncke WH, Boehncke S,. Managing comorbidities in psoriasis. Actas Dermosifiliogr 2009; 100 (Suppl. 2): 22-7.
31. Cohen AD, Dreiher J, Shapiro Y, et al., Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-9. (Pubitemid 351541054)
32. Cohen AD, Sherf M, Vidavsky L, et al., Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-5. (Pubitemid 351158580)
33. Qureshi AA, Choi HK, Setty AR, et al., Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-82.
34. Sommer DM, Jenisch S, Suchan M, et al., Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
35. Neimann AL, Shin DB, Wang X, et al., Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35. (Pubitemid 44556851)
36. Gisondi P, Tessari G, Conti A, et al., Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
37. Gisondi P, Targher G, Zoppini G, et al., Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
38. Gisondi P, Farina S, Giordano MV, et al., Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754-7.
39. Gladman DD, Antoni C, Mease P, et al., Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): ii14-17. (Pubitemid 40288513)
40. Husted JA, Gladman DD, Farewell VT, et al., Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511-17. (Pubitemid 27153417)
41. Zachariae H, Zachariae R, Blomqvist K, et al., Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108-13. (Pubitemid 34596683)
42. Husted JA, Tom BD, Farewell VT, et al., A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 2007; 56: 840-9. (Pubitemid 46399432)
43. McKenna SP, Doward LC, Whalley D, et al., Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63: 162-9. (Pubitemid 38122135)
44. Wallenius M, Skomsvoll JF, Koldingsnes W, et al., Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009; 68: 685-9.
45. Wong K, Gladman DD, Husted J, et al., Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-72. (Pubitemid 27452539)
46. Gladman DD, Farewell VT, Wong K, et al., Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-10. (Pubitemid 28265412)
47. Kimball AB, Jacobson C, Weiss S, et al., The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-92. (Pubitemid 43128290)
48. Lynde CW, Poulin Y, Guenther L, et al., The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009; 13: 235-52.
49. Waters HC, Carter CT, Piech CT,. The impact of psoriasis on psychological functioning and quality of life. J Am Acad Dermatol 2009; 60: AB183.
50. Schmitt JM, Ford DE,. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17-27. (Pubitemid 46976010)
51. Kurd SK, Troxel AB, Crits-Christoph P, et al., The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
52. Eghlileb AM, Davies EE, Finlay AY,. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245-50. (Pubitemid 47029819)
53. Evers AW, Verhoeven EW, Kraaimaat FW, et al., How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol 2010; 163: 986-91.
54. Reich A, Wojcik-Maciejewicz A, Slominski AT,. Stress and the skin. G Ital Dermatol Venereol 2010; 145: 213-19.
55. Jankovic S, Raznatovic M, Marinkovic J, et al., Relevance of psychosomatic factors in psoriasis: a case-control study. Acta Derm Venereol 2009; 89: 364-8.
56. Verhoeven EW, Kraaimaat FW, de Jong EM, et al., Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol 2009; 161: 295-9.
57. Finzi A, Colombo D, Caputo A, et al., Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE study. J Eur Acad Dermatol Venereol 2007; 21: 1161-9. (Pubitemid 47423402)
58. Frangos JE, Kimball AB,. Divorce/marriage ratio in patients with psoriasis compared to patients with other chronic medical conditions. J Invest Dermatol 2008; 128: S87.
59. Magin P, Heading G, Adams J, et al., Sex and the skin: a qualitative study of patients with acne, psoriasis and atopic eczema. Psychol Health Med 2010; 15: 454-62.
60. Sampogna F, Gisondi P, Tabolli S, et al., Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144-50. (Pubitemid 46377240)
61. Poikolainen K, Karvonen J, Pukkala E,. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490-3.
62. Scharloo M, Kaptein AA, Weinman J, et al., Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142: 899-907. (Pubitemid 30304599)
63. Hill L, Kennedy P,. The role of coping strategies in mediating subjective disability in people who have psoriasis. Psychol Health Med 2002; 7: 261-9.
64. Fortune DG, Richards HL, Kirby B, et al., A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002; 146: 458-65. (Pubitemid 34603818)
65. Fortune DG, Richards HL, Griffiths CE, et al., Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. Br J Clin Psychol 2004; 43: 65-82. (Pubitemid 38379783)
66. Krueger G, Koo J, Lebwohl M, et al., The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4. (Pubitemid 32240779)
67. Finlay AY, Coles EC,. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
68. Schmitt JM, Ford DE,. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-10. (Pubitemid 44215193)
69. Horn EJ, Fox KM, Patel V, et al., Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963-71. (Pubitemid 350087343)
70. Sohn S, Schoeffski O, Prinz J, et al., Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137-44. (Pubitemid 43260729)
71. Ben-David G, Sheiner E, Hallak M, et al., Pregnancy outcome in women with psoriasis. J Reprod Med 2008; 53: 183-7. (Pubitemid 351498127)
72. Cohen-Barak E, Nachum Z, Rozenman D, et al., Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2010; doi:. Nov 25 (Epub ahead of print).
73. Lam J, Polifka JE, Dohil MA,. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59: 295-315.
74. Griffiths CE,. Management of psoriasis in pregnancy: time to deliver? Br J Dermatol 2010; 163: 235.
75. Weatherhead S, Robson SC, Reynolds NJ,. Management of psoriasis in pregnancy. BMJ 2007; 334: 1218-20. (Pubitemid 46954588)
76. Yang YW, Chen CS, Chen YH, Lin HC,. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol 2011; 64: 71-7.
77. Unaeze J, Nijsten T, Murphy A, et al., Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006; 126: 1480-9.
78. Sprangers MA, Schwartz CE,. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999; 48: 1507-15. (Pubitemid 29254110)
79. Manuel GM, Roth S, Keefe FJ, et al., Coping with cancer. J Human Stress 1987; 13: 149-58. (Pubitemid 17165251)
80. Cioffi D,. Beyond attentional strategies: cognitive-perceptual model of somatic interpretation. Psychol Bull 1991; 109: 25-41.
81. Warren S, Warren KG, Cockerill R,. Emotional stress and coping in multiple sclerosis (MS) exacerbations. J Psychosom Res 1991; 35: 37-47.
82. Fortune D, Roberts R, Towell T,. Depression in multiple sclerosis: the contribution of psychosocial mediators. Presented at the 10th European Health Psychology Conference, Dublin, Ireland, 1996.
83. Gulliver W,. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl. 2): 2-9.
84. Koo J,. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96. (Pubitemid 26249398)
85. Schmid-Ott G, Kunsebeck HW, Jager B, et al., Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 2005; 85: 27-32. (Pubitemid 40254676)
86. Gupta MA, Gupta AK,. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4: 833-42. (Pubitemid 38030859)
87. Langley RG, Krueger GG, Griffiths CE,. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl. 2): ii18-23. discussion ii4-5. (Pubitemid 40288514)
88. Lerner R, Steinberg L, eds. Handbook of Adolescent Psychology, 2nd edn. New York: Wiley, 2004.
89. Coleman J, Hendry L,. The Nature of Adolescence, 2nd edn. Florence, KY: Taylor & Francis/Routledge, 1990.
90. Alexandroff AB, Pauriah M, Camp RD, et al., More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1-7.
91. Dantzer R, O'Connor JC, Freund GG, et al., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56. (Pubitemid 350295688)
92. Glassman AH, Miller GE,. Where there is depression, there is inflammation. sometimes! Biol Psychiatry 2007; 62: 280-1. (Pubitemid 47454517)
93. Tyring S, Gottlieb A, Papp K, et al., Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35. (Pubitemid 43038667)
94. Baran R,. The burden of nail psoriasis: an introduction. Dermatology 2010; 221 (Suppl. 1): 1-5.
95. de Bes J, Legierse CM, Prinsen CA, et al., Patient education in chronic skin diseases: a systematic review. Acta Derm Venereol 2011; 91: 12-17.
96. McCrae R, Costa PT,. Personality, coping, and coping effectiveness in an adult sample. J Pers 2006; 54: 385-404.
97. Augustin M, Kruger K, Radtke MA, et al., Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72. (Pubitemid 351630108)
98. Nast A, Reytan N, Rosumeck S, et al., Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008; 22: 1337-42.
99. Horn EJ, Fox KM, Patel V, et al., Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57: 957-62. (Pubitemid 350087339)
100. Mrowietz U, Kragballe K, Reich K, et al., Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
101. Renzi C, Di Pietro C, Gisondi P, et al., Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. Acta Derm Venereol 2006; 86: 528-34. (Pubitemid 44950747)
102. Courtenay M, Carey N, Stenner K, et al., Patients views of nurse prescribing: effects on care, concordance and medicine taking. Br J Dermatol 2011; 164: 396-401.
103. Bjarkoy RO, Gjengedal E, Wahl AK,. Care in the context of the complexity of psoriasis. Clin Nurs Res 2011; 20: 47-63.